While clinical data remain limited, eravacycline appears promising for the treatment of infections caused by MDR pathogens, particularly in patients with limited therapeutic options or intolerance to β-lactams. As resistance mechanisms continue to evolve, the role of eravacycline in real-world clinical practice may extend beyond its current indications, warranting further research to define its optimal therapeutic applications.
Vena et al. (Fri,) studied this question.